Pabal

(Carbetocin)

ApprovedSmall molecule

Carbetocin is used to prevent excessive bleeding after childbirth by helping the uterus contract and stay firm. It is an alternative to oxytocin (Pitocin) and may be preferred because its effects last longer.[2] Pabal is currently approved and in use across 8 indications[4].[1]

Pabal is one of 227 small molecule programs targeting Uterine Inertia. It is currently in Approved.

Indications

Total Trials

Active Trials

226

Competitors

Pipeline

Status by Indication[4][1]

Indication

Uterine InertiaActive, not recruiting

Prader-Willi SyndromeActive, not recruiting

HemorrhageActive, not recruiting

Uterine FibroidActive, not recruiting

PreeclampsiaActive, not recruiting

Morbid ObesityActive, not recruiting

Cesarean SectionActive, not recruiting

Postpartum HemorrhageUnknown

Uterine InertiaPreclinical

Active, not recruiting

Prader-Willi SyndromePhase 3

Active, not recruiting

HemorrhagePreclinical

Active, not recruiting

Uterine FibroidPhase 1

Active, not recruiting

PreeclampsiaPreclinical

Active, not recruiting

Morbid ObesityPreclinical

Active, not recruiting

Cesarean SectionApproved

Active, not recruiting

Postpartum HemorrhagePreclinical

Unknown

Competition

Competitive Landscape

230 competitors in Cesarean Section

#DrugCompanyPhaseTrials

Pabal

AACADIA Pharmaceuticals Inc.

Approved

8 2

Dynastat

Pfizer

Preclinical

1 3

Proamatine

Takeda

Preclinical

1 4

Duragesic

CCephalon

Preclinical

6 5

Versed

CConrado Roberto Hoffmann Filho

Preclinical

4 6

Xylocaine

MMEDRx USA, Inc.

Preclinical

4 7

Catapres

Boehringer Ingelheim

Preclinical

4 8

Ancef

BBaxter Healthcare Corporation

Preclinical

3 9

Nubain

AAultman Health Foundation

Preclinical

3 10

Neurontin

VViatris Specialty LLC

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

N/ARecruiting

Blood Loss

NCT07390864

N/ARecruiting

Cesarean Delivery

NCT07187544

Q4 2026

N/ARecruiting

Blood Loss

NCT05266534

Q3 2027

Post-ApprovalNot yet recruiting

Elective

NCT06946589

Q4 2028

Post-ApprovalNot yet recruiting

Postpartum Hemorrhage

NCT07401524

Clinical

Trials by Indication[1]

Postpartum Hemorrhage17 trials

Comparison of the Effect of Carbetocin Versus Oxytocin in the Prevention of Postpartum Hemorrhage After Emergency Caesarean Section in Antenatal Low-risk Patients

Completed·—·N/A·NCT07380529·300 enrolled

Carbetocin Versus Oxytocin Plus Sublingual Misoprostol in the Management of Atonic Postpartum Hemorrhage

Completed·—·N/A·NCT03870503·135 enrolled

Efficacy of Oxytocin vs. Carbetocin in Prevention of Postpartum Hemorrhage After Cesarean Section

Completed·SShahid Beheshti University of Medical Sciences·Phase 2·NCT02079558·220 enrolled

Show 14 more trials

Oral Tranexamic Acid Plus Sublingual Misoprostol in Atonic Postpartum Hemorrhage

Completed·—·N/A·NCT03870256·135 enrolled

Carbetocin Versus Oxytocin for the Prevention of Postpartum Hemorrhage in Emergency Caesarean Delivery

Completed·—·Phase 4·NCT03755531·300 enrolled

Carbetocin Versus Syntocinon for Prevention of Postpartum Hemorrhage in Cardiac Patients Undergoing Caesarean Section

Unknown status·—·Phase 4·NCT05110482·38 enrolled

Comparative Efficacy of Carbetocin and Oxytocin in Parturients at Risk of Atonic Postpartum Hemorrhage Undergoing Elective Cesarean Delivery

Recruiting·SSamuel Lunenfeld Research Institute, Mount Sinai Hospital·N/A·NCT06333340·160 enrolled

Carbetocin Versus Ergometrin in the Prevention of Postpartum Hemorrhage

Unknown status·NNational and Kapodistrian University of Athens·Phase 4·NCT04300452·100 enrolled

Carbetocin Versus Buccal Misoprostol Plus IV Tranexamic Acid for Prevention of Postpartum Hemorrhage at Cesarean Section

Completed·—·N/A·NCT03710317·400 enrolled

Oxytocin, Carbetocin and Misopristol for Treatment of Postpartum Hemorrhage: A Multicentric Randomized Trial

Unknown status·SSohag University·N/A·NCT01600612·300 enrolled

Carbetocin and Oxytocin in Elective Caesarean Section With High Risk of Postpartum Hemorrhage

Completed·GGhamra Military Hospital·Phase 4·NCT02391636·264 enrolled

Prevention of Postpartum Hemorrhage in Patients With Severe Preeclampsia Using Carbetocin Versus Misoprostol

Completed·Kkhalid abd aziz mohamed·Phase 3·NCT02086994·60 enrolled

Carbetocin Versus Syntometrine for Prevention of Postpartum Hemorrhage After Cesarean Section

Completed·—·Phase 4·NCT02044549·300 enrolled

CARBETOCIN VERSUS RECTAL MISOPROSTOL FOR MANAGEMENT OF THIRD STAGE OF LABOR IN WOMEN AT LOW RISK OF POSTPARTUM HEMORRHAGE

Completed·—·Phase 4·NCT03556852·150 enrolled

Carbetocin Versus Oxytocin and Ergometrine for the Prevention of Postpartum Hemorrhage

Completed·—·N/A·NCT03578263·220 enrolled

Carbetocin Uterotonic Treatment in Twin Pregnancies for Prevention of Postpartum Hemorrhage

Not yet recruiting·SSheba Medical Center·Phase 4·NCT07401524·120 enrolled

Carbetocin Versus Misoprostol in High Risk Patients for Postpartum Hemorrhage After C.S.

Unknown status·—·Phase 4·NCT02277067·200 enrolled

Cesarean Delivery9 trials

Effect of Co-administration of Carbetocin and Calcium Chloride on Uterine Tone in Patients Undergoing Elective Cesarean Delivery

Recruiting·SSamuel Lunenfeld Research Institute, Mount Sinai Hospital·N/A·NCT07187544·120 enrolled

Carbetocin Compared To Oxytocin During Cesarean Delivery

Unknown status·—··NCT05758012·260 enrolled

Carbetocin at Cesarean Delivery for Labor Arrest

Completed·SSamuel Lunenfeld Research Institute, Mount Sinai Hospital·N/A·NCT01725243·40 enrolled

Show 6 more trials

Carbetocin at Elective Cesarean Delivery

Completed·SSamuel Lunenfeld Research Institute, Mount Sinai Hospital·N/A·NCT01262742·80 enrolled

Carbetocin at Elective Cesarean Delivery Part 3

Completed·SSamuel Lunenfeld Research Institute, Mount Sinai Hospital·N/A·NCT01651130·40 enrolled

Carbetocin at Elective Cesarean Delivery Part 4

Completed·SSamuel Lunenfeld Research Institute, Mount Sinai Hospital·N/A·NCT02264769·110 enrolled

Database Evaluating Outcomes of Using Carbetocin as the Primary Uterotonic Following Cesarean Delivery

Completed·MMaisonneuve-Rosemont Hospital··NCT03959436·612 enrolled

Carbetocin at Elective Cesarean Delivery Part 2

Completed·SSamuel Lunenfeld Research Institute, Mount Sinai Hospital·N/A·NCT01428817·120 enrolled

ED90 Determination of Carbetocin for the Prevention of Uterine Atony in Women Undergoing an Elective Cesarean Delivery

Unknown status·MMaisonneuve-Rosemont Hospital·Phase 4·NCT01579201·40 enrolled

Cesarean Section8 trials

Effects of Carbetocin and Oxytocin Used in Cesarean Sections on Postoperative Pain

Completed·—··NCT06692621·120 enrolled

Effects of Oxytocin and Carbetocin on Renal System in Cesarean Sections

Unknown status·UUfuk University··NCT03939806·100 enrolled

Efficacy of Carbetocin Versus Oxytocin Plus Misoprostol in Decreasing Blood Loss During Cesarean Section

Completed·—·Phase 4·NCT05664659·90 enrolled

Show 5 more trials

Oxytocin i.m./i.v. Versus Carbetocin i.v. in Elective Cesarean Sections

Completed·UUniversity of Zurich·Phase 4·NCT03651882·550 enrolled

Carbetocin vs. Oxytocin at Elective Cesarean Section

Completed·SSamuel Lunenfeld Research Institute, Mount Sinai Hospital·N/A·NCT03168698·278 enrolled

Comparison of Two Doses of Carbetocin for Prevention of Uterine Atony, During Elective Cesarean Section

Completed·LLaval University·Phase 4·NCT01630187·72 enrolled

Carbetocin Versus Oxytocin Infusion Plus Tranexamic Acid During Cesarean Section

Unknown status·—·N/A·NCT03777878·400 enrolled

The Use of Oxytocin, Carbetocin and Buccal Misoprostol in Patients Undergoing Elective Cesarean Section (CS)

Completed·—·Phase 3·NCT02053922·270 enrolled

CAR4 trials

Carbetocin on Myocardial Repolarization Dynamics in Obstetrics Study

Completed·UUniversity of British Columbia·Phase 4·NCT03716076·50 enrolled

Comparing the Dose-response Profiles of Uterotonics After Initial Carbetocin Administration - an Ex-vivo Study in Desensitized Human Myometrium

Recruiting·SSamuel Lunenfeld Research Institute, Mount Sinai Hospital·N/A·NCT06285409·32 enrolled

Effect of Extracellular Calcium on Carbetocin Mediated Contractility in Human Myometrium

Recruiting·SSamuel Lunenfeld Research Institute, Mount Sinai Hospital·N/A·NCT06930391·40 enrolled

Show 1 more trial

A Study to Evaluate the Effect of Carbetocin on the QT/QTc Interval in Healthy Subjects

Completed· Ferring logo

Ferring·Phase 1·NCT05924321·40 enrolled

Randomised Controlled Trial3 trials

Carbetocin Versus Oxytocin in the Prevention of Post Partum Haemorrhage (PPH) in Women Delivered Vaginally With at Least 2 Risk Factors for Atonic PPH: A Randomised Controlled Trial

Completed·—·Phase 3·NCT02304042·200 enrolled

Carbetocin Versus Oxytocin in the Management of Atonic Post Partum Haemorrhage (PPH) in Women Delivered Vaginally: A Randomised Controlled Trial

Completed·—·Phase 3·NCT02304055·100 enrolled

Carbetocin Versus Oxytocin in the Prevention of Post Partum Haemorrhage (PPH) in Women Undergoing Caesarean Sections for Placenta Previa: A Randomised Controlled Trial

Unknown status·—·Phase 3·NCT02303418·500 enrolled

29 more indications

Trial3 trials

Carbetocin Myocardium Trial 2014 Part 2

Completed·OOslo University Hospital·Phase 4·NCT03899961·240 enrolled

Intramuscular Oxytocics: A Randomised Control Trial

Completed·NNorth Bristol NHS Trust·Phase 3·NCT02216383·5,798 enrolled

The Clinical Carbetocin Myocardium Trial

Completed·OOslo University Hospital·Phase 4·NCT02528136·40 enrolled

Blood Loss3 trials

Ergometrine Versus Carbetocin to Decrease Blood Loss in Myomectomy

Recruiting·—·N/A·NCT07390864·40 enrolled

The Effect of Intramyometrial Injection of Terlipressin Versus Carbitocin on Hemoglobin and Blood Loss During Open Myomectomy Operations Without Using Haemostatic Tourniquets

Recruiting·WWael Elbanna Clinic·N/A·NCT05266534·162 enrolled

Methods to Reduce Blood Loss in Abdominal Myomectomy

Unknown status·—·Phase 4·NCT04595812·120 enrolled

Elective2 trials

Cardiac Changes After Effective Dose Carbetocin for Elective Caesarian Section

Not yet recruiting·JJordan Leitch·Phase 4·NCT06946589·200 enrolled

Carbetocin at Elective Cesarean Deliveries: A Dose-finding Study in Women With BMI ≥ 40kg/m2

Completed·SSamuel Lunenfeld Research Institute, Mount Sinai Hospital·N/A·NCT03672045·30 enrolled

Preeclampsia2 trials

Uterotonics for Severe Preeclampsia

Completed·—·N/A·NCT04756661·124 enrolled

Carbetocin vs. Oxytocin for Prevention of Postpartum Bleeding in Patients With Severe Preeclampsia

Unknown status·SSaint Thomas Hospital, Panama·Phase 3·NCT01382732·636 enrolled

Hemorrhage2 trials

Carbetocin Versus Oxytocin for Prophylaxis Against Atonic Primary Post-partum Hemorrhage

Unknown status·SSohag University·N/A·NCT05479357·80 enrolled

Carbetocin Versus Oxytocin for Prevention of Postcesarean Hemorrhage in Pregnancy With High Risk for PPH

Completed·DDepartment of Medical Services Ministry of Public Health of Thailand·Phase 1·NCT04089176·120 enrolled

Misoprostol2 trials

Misoprostol+Oxytocin vs. Carbetocin in CS

Completed·—·Phase 2/3·NCT02786992·600 enrolled

Carbetocin Versus Misoprostol. A Retrospective Comparative Study

Completed·PPort Said University hospital··NCT04313218·300 enrolled

Prader-Willi syndrome2 trials

Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome

Active, not recruiting·AACADIA Pharmaceuticals Inc.·Phase 3·NCT06173531·170 enrolled

OLE Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome

Enrolling by invitation·AACADIA Pharmaceuticals Inc.·Phase 3·NCT06420297·160 enrolled

Cardiovascular2 trials

Cardiovascular Effects of Carbetocin Given During Elective Cesarean

Completed·UUniversity of British Columbia·Phase 4·NCT02636816·57 enrolled

Haemodynamic and Cardiovascular Effects of Carbetocin and Oxytocin

Completed·UUniversiti Kebangsaan Malaysia Medical Centre·N/A·NCT01719952·50 enrolled

Morbid Obesity1 trial

Oxytocin vs Carbetocin at Cesarean Delivery in Women With Morbid Obesity

Completed·SSamuel Lunenfeld Research Institute, Mount Sinai Hospital·N/A·NCT04902729·48 enrolled

Acute1 trial

Effect of the Uterotonic Carbetocin on Acute Post Cesarean-Section Pain

Unknown status·IInsel Gruppe AG, University Hospital Bern·Phase 4·NCT02642263·78 enrolled

Vaginal Delivery1 trial

Carbetocin Versus Oral Tranexamic Acid Plus, Buccal Misoprostol on Blood Loss After Vaginal Delivery

Completed·—·N/A·NCT03708497·360 enrolled

Pregnancy1 trial

Carbetocin at Elective Cesarean Deliveries: A Dose-finding Study in Women With Twin Pregnancy.

Completed·SSamuel Lunenfeld Research Institute, Mount Sinai Hospital·N/A·NCT04182360·30 enrolled

Intravenous1 trial

Evaluating Efficacy of Intravenous Carbetocin Versus Intramyometrial Injection of Adrenaline in Reducing Blood Loss

Completed·EEgymedicalpedia·Phase 1·NCT05986266·62 enrolled

Post Partum Haemorrhage1 trial

Carbetocin Versus Ergometrine in the Management of Atonic Post Partum Haemorrhage (PPH) in Women Delivered Vaginally

Unknown status·—·Phase 3·NCT02410759·200 enrolled

Oxytocin1 trial

Comparison Of The Effects Of Carbetocin And Oxytocin In C-Sectıon

Unknown status·—·Phase 4·NCT05742854·200 enrolled

Caesarean Section1 trial

Carbetocin Versus Oxytocin in Caesarean Section for the Control of Postpartum Haemorrhage

Unknown status·—·Phase 1·NCT02396303·100 enrolled

Analgesic1 trial

Analgesic Effect of Oxytocin Receptor Modulation

Completed·IInsel Gruppe AG, University Hospital Bern·N/A·NCT01918475·25 enrolled

Obese Women1 trial

Carbetocin Versus Syntometrine in Obese Women Undergoing Elective Cesarean

Completed·—·Phase 4·NCT03693599·1,200 enrolled

Tranexamic Acid1 trial

Intravenous Tranexamic Acid Versus IV Carbetocin in Abdominal Myomectomy

Unknown status·—·Phase 4·NCT04357015·153 enrolled

Infusion1 trial

Impact of Carbetocin Administration on Heart Rate When Given as an Infusion Versus as a Bolus.

Completed·CCiusss de L'Est de l'Île de Montréal·Phase 4·NCT03404544·70 enrolled

Hemodynamic1 trial

Carbetocin Versus Oxytocin and Hemodynamic Effects

Completed·OOslo University Hospital·Phase 4·NCT00977769·76 enrolled

Intraoperative1 trial

the Effect of Carbetocin in Decreasing Intraoperative Blood Loss in Abdominal Myomectomy

Completed·—·Phase 4·NCT04083625·138 enrolled

Hysteroscopic Myomectomy1 trial

Intraoperative Carbetocin to Decrease Blood Loss During Hysteroscopic Myomectomy

Completed·MMansoura University Hospital·Phase 4·NCT04482959·40 enrolled

Placenta Previa1 trial

Carbetocin Versus Misoprostol in Cases With Placenta Previa After C.S.

Unknown status·—·Phase 4·NCT02277041·200 enrolled

Bleeding1 trial

Methods Decreasing Bleeding in Open Myomectomy

Unknown status·—·Phase 4·NCT05806307·105 enrolled

Treatment1 trial

Carbetocin vs. Oxytocin: In-vitro Myometrial Contractions With and Without Oxytocin Pre-treatment

Completed·SSamuel Lunenfeld Research Institute, Mount Sinai Hospital·N/A·NCT01689298·20 enrolled

Clinical Trial1 trial

Randomized Clinical Trial for Comparison Of Intravenous Carbeitocin Versus Oxytocin In Management Of Placental Delivery In Second Trimester Interruption

Unknown status·WWafaa Uthman Ahmed·Phase 4·NCT01827124·140 enrolled

Prevention1 trial

Carbetocin in the Prevention of Primary Postpartum Haemorrhage

Completed·MMinistry of Health and Population, Egypt··NCT06159959·244 enrolled

Unspecified1 trial

EMG for Uterotonic Efficiency Estimation

Completed·UUniversity Medical Centre Ljubljana·N/A·NCT04201665·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 80 trial records for Carbetocin. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Pabal drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Carbetocin compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Carbetocin. EMBL-EBI & Wellcome Sanger Institute.
[5]
SEC EDGAR — ACADIA Pharmaceuticals Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Oxytocin Receptor Agonist[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: AACADIA Pharmaceuticals Inc.

Pabal

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Q3 2027

Q4 2028

Trials by Indication[1]

Postpartum Hemorrhage17 trials

Cesarean Delivery9 trials

Cesarean Section8 trials

CAR4 trials

Randomised Controlled Trial3 trials

Trial3 trials

Blood Loss3 trials

Elective2 trials

Preeclampsia2 trials

Hemorrhage2 trials

Misoprostol2 trials

Prader-Willi syndrome2 trials

Cardiovascular2 trials

Morbid Obesity1 trial

Acute1 trial

Vaginal Delivery1 trial

Pregnancy1 trial

Intravenous1 trial

Post Partum Haemorrhage1 trial

Oxytocin1 trial

Caesarean Section1 trial

Analgesic1 trial

Obese Women1 trial

Tranexamic Acid1 trial

Infusion1 trial

Hemodynamic1 trial

Intraoperative1 trial

Hysteroscopic Myomectomy1 trial

Placenta Previa1 trial

Bleeding1 trial

Treatment1 trial

Clinical Trial1 trial

Prevention1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News